Verified July 2026 · Cited to primary sources
Cagrilintide: Evidence Grade B. Real human trials, limited or historical.
The honest verdict
Grade B and genuinely promising, but the key fact is that it is not FDA-approved as a standalone drug. The real-world path for cagrilintide is as the amylin half of the CagriSema combination, which posted roughly 20 percent weight loss in phase 3. If you want something you can actually get today, that means an approved GLP-1: see glp1picks.com for those. Do not source cagrilintide from research-chemical vendors.
Cagrilintide at a glance
- Class
- Long-acting amylin receptor agonist
- Mechanism
- A long-acting analog of amylin, the pancreatic hormone co-secreted with insulin. It acts on amylin and calcitonin receptors to slow gastric emptying, suppress glucagon, and promote satiety through a pathway distinct from GLP-1. The interest is in stacking it with a GLP-1 agonist (semaglutide) to hit two separate appetite mechanisms at once, which is the CagriSema strategy.
- Also known as
- AM833, NNC0174-0833
- Research applications
- Investigational weight management (standalone and combination)
- Component of the CagriSema fixed combination in phase 3
- Forms
- Subcutaneous injection (weekly, investigational)
- Legal status
- Research-only
- WADA (anti-doping)
- Not on the WADA Prohibited List (2025). As an investigational agent it is not separately classified; amylin analogs are not considered performance-enhancing.
- Evidence grade
- Grade BReal human trials, limited or historical
How we grade evidence
Every grade comes from a fixed A to F rubric: human-trial strength, not hype or affiliate status. Last verified July 6, 2026.
What is Cagrilintide?
An investigational once-weekly amylin analog that produced about 11 percent weight loss on its own in phase 2 and is the partner half of the CagriSema combination, not an approved standalone drug.
A long-acting analog of amylin, the pancreatic hormone co-secreted with insulin. It acts on amylin and calcitonin receptors to slow gastric emptying, suppress glucagon, and promote satiety through a pathway distinct from GLP-1. The interest is in stacking it with a GLP-1 agonist (semaglutide) to hit two separate appetite mechanisms at once, which is the CagriSema strategy.
How strong is the evidence for Cagrilintide?
Not FDA-approved. Evidence rests on positive human trials short of standalone approval. A phase 2 dose-finding trial showed cagrilintide 4.5 mg produced about 10.8 percent weight loss at 26 weeks versus 3.0 percent on placebo, and beat liraglutide 3.0 mg. In the phase 3 REDEFINE 1 trial the CagriSema combination reached roughly 20 percent weight loss. Strong phase 2 and 3 human data, but no standalone approval, so grade B.
Primary sources (2)
Is Cagrilintide legal? (Status July 2026)
No legal supervised US route.
What is Cagrilintide used for?
Cagrilintide is marketed for the goals below. See how it ranks against other peptides in each, by evidence, not hype.
What does Cagrilintide cost, and how do you access it legally?
Typical cost
Not commercially available
Cagrilintide is investigational and not sold as an approved standalone product, so there is no legitimate consumer price. Approved GLP-1 options and their real pricing are covered on our sister site glp1picks.com.
No legal supervised access route right now.
Cagrilintide has no compliant US route today. Vials sold "for research use only" are a gray-market fig-leaf, not a legal loophole, so we don't link them. If you pursue Cagrilintide, do it with a licensed clinician, and re-check its legal status first.
Trying to lose weight?
For weight loss, an approved GLP-1 beats this peptide.
No research peptide here has proven, legally-available weight-loss data that beats an approved GLP-1. Our sister site compares the options that actually work.
Is Cagrilintidesafe? Side effects & risks
Investigational, so its long-term safety is not established the way the approved GLP-1s are. In trials the most common effects were gastrointestinal (nausea, constipation, diarrhea) and injection-site reactions, broadly similar in character to the GLP-1 class. Amber reflects the investigational status and the absence of large multi-year safety data on the standalone molecule, not a specific alarming signal. It is not legally available for compounding or general use.
Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.
FAQ
Cagrilintide FAQ
Can I buy cagrilintide?
Not legitimately. It is investigational, not FDA-approved as a standalone drug, and not eligible for pharmacy compounding. Vials sold by research-chemical sites are unregulated and unverified. If you want an approved weight-loss option you can actually obtain, see glp1picks.com.
How is cagrilintide different from semaglutide?
They work through entirely different hormones. Semaglutide is a GLP-1 agonist; cagrilintide is an amylin analog. That is the whole point of combining them in CagriSema: two separate appetite pathways at once, which in phase 3 produced greater weight loss than either component alone.
How much weight did cagrilintide cause on its own?
In its phase 2 dose-finding trial, the 4.5 mg dose produced about 10.8 percent body-weight loss at 26 weeks, versus 3.0 percent on placebo, and outperformed liraglutide 3.0 mg. Combined with semaglutide as CagriSema, phase 3 weight loss reached roughly 20 percent.
From our portfolio
Tracking Cagrilintide?
Titrate is an iOS app for logging doses, schedules and progress over time, with a reconstitution calculator built in. It tracks, it does not prescribe.
Keep reading
MOTS-c
An "exercise-mimetic" metabolic peptide. Real mechanistic interest, but human evidence is association-only.
Grade ATesamorelin
One of only two FDA-approved peptides in this space. Proven to cut visceral fat, but approved for a narrow HIV indication.
Grade BRetatrutide
The next-generation weight-loss peptide with the strongest efficacy signal. But it is investigational and not yet available by any legal route.
The monthly peptide evidence brief.
What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.